Celgene Corporation Has Another Very Positive Options Trading Session

 Celgene Corporation Has Another Very Positive Options Trading Session

In today’s session Celgene Corporation (CELG) registered an unusually high (1,111) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious CELG increase. With 1,111 contracts traded and 2234 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: CELG161021C00113000 closed last at: $0.43 or 7.5% up. About 786,653 shares traded hands. Celgene Corporation (NASDAQ:CELG) has risen 2.49% since March 3, 2016 and is uptrending. It has underperformed by 5.85% the S&P500.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on November, 3. They expect $1.31 earnings per share, up 16.96% or $0.19 from last year’s $1.12 per share. CELG’s profit will be $1.02B for 19.93 P/E if the $1.31 EPS becomes a reality. After $1.28 actual earnings per share reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 2.34% EPS growth.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Out of 20 analysts covering Celgene Corporation (NASDAQ:CELG), 17 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 85% are positive. $190 is the highest target while $83 is the lowest. The $137.29 average target is 31.48% above today’s ($104.42) stock price. Celgene Corporation has been the topic of 36 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Standpoint Research on Thursday, January 14. Leerink Swann initiated the stock with “Market Perform” rating in Friday, February 5 report. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Friday, July 15 by Stifel Nicolaus. The firm earned “Buy” rating on Thursday, September 29 by Citigroup. Jefferies initiated the shares of CELG in a report on Wednesday, September 9 with “Buy” rating. As per Tuesday, September 1, the company rating was initiated by Raymond James. The rating was maintained by RBC Capital Markets on Friday, January 29 with “Outperform”. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Friday, November 6 by Canaccord Genuity. The stock of Celgene Corporation (NASDAQ:CELG) has “Outperform” rating given on Wednesday, August 12 by Cowen & Co. The firm has “Buy” rating by Jefferies given on Wednesday, October 5.

According to Zacks Investment Research, “Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.”

Insitutional Activity: The institutional sentiment increased to 0.99 in Q2 2016. Its up 0.06, from 0.93 in 2016Q1. The ratio is positive, as 70 funds sold all Celgene Corporation shares owned while 411 reduced positions. 60 funds bought stakes while 418 increased positions. They now own 587.22 million shares or 5.24% less from 619.66 million shares in 2016Q1.
Philadelphia Trust accumulated 0.69% or 80,326 shares. Smith Moore & last reported 3,783 shares in the company. Ardsley Advisory Prns accumulated 85,500 shares or 1.46% of the stock. Blackrock Limited Company last reported 2.21M shares in the company. Point72 Asia (Hong Kong) Ltd accumulated 2.25% or 19,646 shares. Bremer Trust National Association reported 46,969 shares or 1.29% of all its holdings. Mizuho Asset Mngmt Coltd owns 21,495 shares or 0.38% of their US portfolio. Mirae Asset Glob Invs has invested 0.88% of its portfolio in Celgene Corporation (NASDAQ:CELG). Toronto Dominion National Bank accumulated 4,297 shares or 0% of the stock. Qcm Cayman accumulated 0.65% or 15,134 shares. Andra Ap has invested 0.09% of its portfolio in Celgene Corporation (NASDAQ:CELG). The New York-based Blackrock has invested 0.28% in Celgene Corporation (NASDAQ:CELG). The California-based Everett Harris And Communication Ca has invested 0.02% in Celgene Corporation (NASDAQ:CELG). Sivik Global Lc last reported 55,000 shares in the company. Fiera Cap has 43,269 shares for 0.02% of their US portfolio.

Insider Transactions: Since July 28, 2016, the stock had 0 insider purchases, and 7 selling transactions for $29.76 million net activity. Shares for $2.22M were sold by BARKER RICHARD W on Friday, September 23. Shares for $1.64 million were sold by MARIO ERNEST on Friday, September 23. CASEY MICHAEL D also sold $4.92M worth of Celgene Corporation (NASDAQ:CELG) shares. Shares for $3.14 million were sold by LOUGHLIN JAMES J. On Thursday, September 15 the insider KAPLAN GILLA sold $1.03 million. $11.00 million worth of Celgene Corporation (NASDAQ:CELG) was sold by HUGIN ROBERT J. On Monday, October 3 the insider Friedman Michael A sold $5.82 million.

Celgene Corporation is a biopharmaceutical company. The company has a market cap of $81.42 billion. The Firm together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. It has a 43.84 P/E ratio. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin).

CELG Company Profile

Celgene Corporation (Celgene), incorporated on April 17, 1986, is a biopharmaceutical company. The Firm together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology. Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

More important recent Celgene Corporation (NASDAQ:CELG) news were published by: Finance.Yahoo.com which released: “Celgene Corporation to Announce Third Quarter 2016 Results on October 27, 2016” on October 03, 2016, also Businesswire.com published article titled: “Celgene Announces Acceptance of Late Breaking GED-0301 CD-001 Abstract at the …”, Globenewswire.com published: “Celgene Corporation (Nasdaq: CELG) to Ring The Nasdaq Stock Market Closing Bell” on September 08, 2016. More interesting news about Celgene Corporation (NASDAQ:CELG) was released by: Investorplace.com and their article: “Celgene Corporation (CELG) – Two Ways to Trade CELG Stock” with publication date: September 09, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment